Patient and disease characteristics
. | Study group . | . | . | |
|---|---|---|---|---|
| Parameter . | Imatinib mesylate . | IFN-α . | P . | |
| Age | ||||
| 60 y or older, no. (%) | 68 (24) | 83 (13) | < .01 | |
| Median, y (range) | 48 (15-84) | 43 (15-76) | < .01 | |
| Splenomegaly | 83 (30) | 230 (35) | .10 | |
| Hemoglobin | ||||
| Less than 120 g/L, no. (%) | 113 (41) | 243 (37) | .37 | |
| Median, g/L (range) | 124 (62-167) | 125 (50-171) | .09 | |
| WBC count | ||||
| More than 40 × 109/L, no. (%) | 113 (41) | 342 (53) | < .01 | |
| Median, × 109/L (range) | 27.3 (1.6-283) | 44.4 (2.1-556) | < .01 | |
| Platelets | ||||
| More than 450 × 109/L, no. (%) | 88 (32) | 258 (40) | .02 | |
| Median, × 109/L (range) | 358 (58-1476) | 393 (76-2795) | .05 | |
| Peripheral basophils | ||||
| 7% or more, no. (%) | 56 (20) | 110 (7) | .26 | |
| Median % (range) | 3 (0-19) | 2 (0-19) | < .01 | |
| Peripheral blasts | ||||
| 1%-3%, no. (%) | 88 (32) | 169 (26) | .13 | |
| 4% or more, no. (%) | 11 (4) | 39 (6) | ||
| Median, % (range) | 0 (0-12) | 0 (0-13) | .59 | |
| Marrow basophils | ||||
| 4% or more, no. (%) | 86 (31) | 124 (19) | < .01 | |
| Median, % (range) | 2 (0-15) | 1 (0-15) | < .01 | |
| Marrow blasts | ||||
| 5% or more, no. (%) | 23 (8) | 40 (6) | .26 | |
| Median, % (range) | 2 (0-14) | 1 (0-14) | < .01 | |
| Cytogenetic clonal evolution, no. (%) | 14 (5) | 42 (6) | .48 | |
| Chronic phase lasting 4 mo or more, no. (%) | 16 (6) | 180 (28) | < .01 | |
| Sokal risk | ||||
| Low, no. (%) | 174 (62) | 430 (66) | .25 | |
| Intermediate, no. (%) | 79 (28) | 150 (23) | ||
| High, no. (%) | 26 (9) | 67 (10) | ||
| NA, no. (%) | 0 (0) | 3 (0.5) | ||
| Hasford risk | ||||
| Low, no. (%) | 158 (57) | 407 (63) | .01* | |
| Intermediate, no. (%) | 110 (39) | 178 (27) | ||
| High, no. (%) | 11 (4) | 21 (3) | ||
| NA, no. (%) | 0 (0) | 44 (7) | ||
. | Study group . | . | . | |
|---|---|---|---|---|
| Parameter . | Imatinib mesylate . | IFN-α . | P . | |
| Age | ||||
| 60 y or older, no. (%) | 68 (24) | 83 (13) | < .01 | |
| Median, y (range) | 48 (15-84) | 43 (15-76) | < .01 | |
| Splenomegaly | 83 (30) | 230 (35) | .10 | |
| Hemoglobin | ||||
| Less than 120 g/L, no. (%) | 113 (41) | 243 (37) | .37 | |
| Median, g/L (range) | 124 (62-167) | 125 (50-171) | .09 | |
| WBC count | ||||
| More than 40 × 109/L, no. (%) | 113 (41) | 342 (53) | < .01 | |
| Median, × 109/L (range) | 27.3 (1.6-283) | 44.4 (2.1-556) | < .01 | |
| Platelets | ||||
| More than 450 × 109/L, no. (%) | 88 (32) | 258 (40) | .02 | |
| Median, × 109/L (range) | 358 (58-1476) | 393 (76-2795) | .05 | |
| Peripheral basophils | ||||
| 7% or more, no. (%) | 56 (20) | 110 (7) | .26 | |
| Median % (range) | 3 (0-19) | 2 (0-19) | < .01 | |
| Peripheral blasts | ||||
| 1%-3%, no. (%) | 88 (32) | 169 (26) | .13 | |
| 4% or more, no. (%) | 11 (4) | 39 (6) | ||
| Median, % (range) | 0 (0-12) | 0 (0-13) | .59 | |
| Marrow basophils | ||||
| 4% or more, no. (%) | 86 (31) | 124 (19) | < .01 | |
| Median, % (range) | 2 (0-15) | 1 (0-15) | < .01 | |
| Marrow blasts | ||||
| 5% or more, no. (%) | 23 (8) | 40 (6) | .26 | |
| Median, % (range) | 2 (0-14) | 1 (0-14) | < .01 | |
| Cytogenetic clonal evolution, no. (%) | 14 (5) | 42 (6) | .48 | |
| Chronic phase lasting 4 mo or more, no. (%) | 16 (6) | 180 (28) | < .01 | |
| Sokal risk | ||||
| Low, no. (%) | 174 (62) | 430 (66) | .25 | |
| Intermediate, no. (%) | 79 (28) | 150 (23) | ||
| High, no. (%) | 26 (9) | 67 (10) | ||
| NA, no. (%) | 0 (0) | 3 (0.5) | ||
| Hasford risk | ||||
| Low, no. (%) | 158 (57) | 407 (63) | .01* | |
| Intermediate, no. (%) | 110 (39) | 178 (27) | ||
| High, no. (%) | 11 (4) | 21 (3) | ||
| NA, no. (%) | 0 (0) | 44 (7) | ||
NA indicates not applicable.
P value for the known Hasford categories.